Novavax Inc (NVAX)
Novavax Announces Entering into a License Agreement with Pfizer
RAPT Therapeutics Inc (RAPT)
CAN FITE BIO (CANF)
Cidara Therapeutics Inc. (CDTX)
NervGen Pharma Corp. (NGENF)
NervGen Pharma to Ring the Nasdaq Closing Bell on January 22, 2026, Celebrating Its Recent Nasdaq Listing
Mind Medicine (MNMD)
Definium Therapeutics Introduces Rerouting Minds, an Educational Campaign Exploring the Potential of Pharmaceutical Lysergide (LSD) in Me...
CAN FITE BIO (CANF)
Can-Fite Completes Patient Enrollment in Phase 2a Pancreatic Cancer Study of Namodenoson
908 Devices Inc (MASS)
908 Devices Inc. - 908 Devices Announces Strong Preliminary Financial Results for Fourth Quarter and Full Year 2025
Glaukos Corporation (GKOS)
Glaukos to Release Fourth Quarter and Full Year 2025 Financial Results after Market Close on February 17
Bio-Techne Corp (TECH)
Bio-Techne to Host Conference Call on February 4, 2026, to Announce Second Quarter Fiscal 2026 Financial Results
Bristol-Myers Squibb Company (BMY)
Bristol Myers Squibb - Bristol Myers Squibb Announces Collaboration with Microsoft to Advance AI-Driven Early Detection of Lung Cancer
Bristol-Myers Squibb Co. (BMYMP)
Bristol Myers Squibb Announces Collaboration with Microsoft to Advance AI-Driven Early Detection of Lung Cancer
Bristol-Myers Squibb Company (BMY)
Bristol Myers Squibb Announces Collaboration with Microsoft to Advance AI-Driven Early Detection of Lung Cancer
Adlai Nortye Ltd (ANL)
Merck & Company Inc (MRK)
Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA® (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection